Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 13;13(12):e0209033.
doi: 10.1371/journal.pone.0209033. eCollection 2018.

Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: A repeated cross-sectional study

J M Madden  1 , M J Duffy  2 , L Zgaga  3 , K Bennett  1
Affiliations

Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: A repeated cross-sectional study

J M Madden et al. PLoS One. .

Abstract

Background: Vitamin D has been linked with improved survival after breast cancer diagnosis but little is known about prescribing rates. This study investigates trends in vitamin D supplement use in both a general female and breast cancer population.

Methods: Women with a breast cancer diagnosis were identified from the National Cancer Registry of Ireland (n = 19870). Women who had any vitamin D claim between 2005 and 2011 were identified from pharmacy claims data (n = 8556). Prevalence rates were calculated as a proportion of all eligible women and by age (< 55 years, ≥ 55 years). Poisson regression was used to compare rates of vitamin D prescribing across years (risk ratio (RR), 95% CI).

Results: There was a statistically significant increase in women with a claim for vitamin D between 2005-2011, with the largest increase among breast cancer patients aged ≥ 55 years (RR = 2.26; 95% CI, 2.11-2.42).

Conclusion: This may have significant public health implications if associations between vitamin D and improved breast cancer survival prove to be causal.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
Overall trends in rate of women in receipt of any vitamin D per 1000 women for (i) GMS eligible national population and (ii) GMS breast cancer patients for years 2005–2011 with stratification by age group. Relative risks (RR) along with confidence intervals (CI) are also presented comparing 2011 to 2005 where the referent group for each RR is the group specific level in 2005.
See this image and copyright information in PMC

References

    1. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. British journal of cancer. 2014;110(11):2772–84. 10.1038/bjc.2014.175 - DOI - PMC - PubMed
    1. Li M, Chen P, Li J, Chu R, Xie D, Wang H. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2014;99(7):2327–36. 10.1210/jc.2013-4320 - DOI - PubMed
    1. Vaughan-Shaw PG, O'Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. British journal of cancer. 2017. - PMC - PubMed
    1. Yao S, Kwan ML, Ergas IJ, Roh JM, Cheng TD, Hong CC, et al. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study. JAMA oncology. 2017;3(3):351–7. 10.1001/jamaoncol.2016.4188 - DOI - PMC - PubMed
    1. Cashman KD, Dowling KG, Skrabakova Z, Gonzalez-Gross M, Valtuena J, De Henauw S, et al. Vitamin D deficiency in Europe: pandemic? The American journal of clinical nutrition. 2016;103(4):1033–44. 10.3945/ajcn.115.120873 - DOI - PMC - PubMed

Publication types